TCT-91 Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis.

Ariel Roguin,David E. Kandzari,Erez Marcusohn,Jacques J. Koolen,Gheorghe Doros,Joseph M. Massaro,Hector M. Garcia-Garcia,Johan Bennett,Elie Gharib,Donald E. Cutlip,Ron Waksman

TCT-91 Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis.

2018

Ariel Roguin
David E. Kandzari
Erez Marcusohn
Jacques J. Koolen
Gheorghe Doros
Joseph M. Massaro
Hector M. Garcia-Garcia
Johan Bennett
Elie Gharib
Donald E. Cutlip
Ron Waksman

Presentation with acute coronary syndrome (ACS) constitutes a high-risk subset of patients with worse outcomes following percutaneous coronary intervention (PCI) compared to stable coronary artery disease (CAD). Clinical outcomes were investigated from the BIOFLOW-V trial comparing an ultrathin

Keywords:

Percutaneous coronary intervention
Revascularization
Sirolimus
Subgroup analysis
Internal medicine
Coronary artery disease
Medicine
Acute coronary syndrome
Cardiology
Everolimus
in patient
Conventional PCI
bioresorbable polymers

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations